The authors therefore concluded that treatment with low-dose FK506 (2 ng/mL) was safe but that a larger multi-center trial among BMPR2-deficient PAH patients is needed to establish efficacy [153]. This evidence concerns the gene BMPR2 and pulmonary arterial hypertension.